Issue Investigation and Practices in Discovery Toxicology

[1]  Adriaan P IJzerman,et al.  Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide. , 2013, Journal of medicinal chemistry.

[2]  F W Lee,et al.  Testing paradigm for prediction of development-limiting barriers and human drug toxicity. , 2004, Chemico-biological interactions.

[3]  Seshadri Neervannan,et al.  Preclinical formulations for discovery and toxicology: physicochemical challenges , 2006, Expert opinion on drug metabolism & toxicology.

[4]  Dolores Diaz,et al.  Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid , 2015, Toxicology mechanisms and methods.

[5]  D Parent-Massin,et al.  Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[6]  D. Sampath,et al.  Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[8]  Deepak Sampath,et al.  Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. , 2015, Pharmacology & therapeutics.

[9]  J A Swenberg,et al.  Alpha 2u-globulin nephropathy: review of the cellular and molecular mechanisms involved and their implications for human risk assessment. , 1993, Environmental health perspectives.

[10]  L. Saltz,et al.  The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor , 2008, Investigational New Drugs.

[11]  Rolf Larsson,et al.  A Phase I study of CHS 828 in patients with solid tumor malignancy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  G T Miwa,et al.  The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. , 2000, Toxicology and applied pharmacology.

[13]  S. Gad,et al.  Nonclinical Vehicle Use in Studies by Multiple Routes in Multiple Species , 2006, International journal of toxicology.

[14]  Karl H. Clodfelter,et al.  Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[15]  Xukun Chen,et al.  Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase , 2014, Chembiochem : a European journal of chemical biology.

[16]  Dolores Diaz,et al.  Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.